Optimizing Y90 Therapy for Radiation Lobectomy
Part of paid clinical trials in Jacksonville, Florida.
- Sponsor
- Northwestern University
- Study ID
- NCT04390724
- Status
- Recruiting
Conditions
- Adult Primary Liver Cancer
- HCC
- Metastatic Cancer
- Resection
- Transplant
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Y90 radioembolization — DEVICEPatients with HCC who are eligible to receive standard-of-care Y90 radioembolization and are hepatic resection candidates with inadequate future liver remnant
Study Details
HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care. The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1.
Key Dates
- Start date
- Jul 17, 2020
- Status verified
- Jul 2025
- Primary completion
- Jul 31, 2026
- Completion
- Jul 31, 2026
Study Design
- Enrollment
- 104 participants (estimated)
Arms
- Arm: Patient Group 1: Y90 Standard-of-CareThe first group of patients will be treated with Y90 dose and embolic load as per standard-of-care
- Arm: Patient Group 2: Y90 Dose determined by results from Group 1The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1
Primary Outcome Measure
Patient Group 1: Y90 Glass Microspheres [ Time Frame: 2 years ]
Central Contacts
- Robert Lewandowski, MD312-695-9121
- Kristie Kennedy, MA312-695-4023
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic | Jacksonville | Florida | 32224 | - |
| Northwestern University | Chicago | Illinois | 60611 | Robert Lewandowski, MD (PRINCIPAL_INVESTIGATOR) Jeremy Collins, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Jacksonville, FL
By condition
By specialty
Related Studies
- Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic CancersPHASE1 · Recruiting · University of Chicago · Chicago, Illinois
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1/PHASE2 · Recruiting · PMV Pharmaceuticals, Inc · Irvine, California
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsPHASE1/PHASE2 · Recruiting · Artios Pharma Ltd · Birmingham, Alabama
- MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid TumorsPHASE1 · Recruiting · Memgen, Inc. · Tampa, Florida